Isil Altintas
Utrecht, UT, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
Journal: Journal for immunotherapy of cancer
Published: April 26, 2022
An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
Journal: Oncoimmunology
Published: February 21, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Journal: Cancer discovery
Published: October 18, 2021
Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles.
Journal: Biomaterials
Published: September 10, 2013
Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways.
Journal: Molecular pharmaceutics
Published: July 30, 2013
Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: September 03, 2012
Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis.
Journal: Angewandte Chemie (International ed. in English)
Published: April 08, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026